Abstract 1912: Time to close the gaps in #PsA care RISE Registry reveals: - higher disease activity in the South - more oral steroids + csDMARDs, fewer bDMARDs, and more comorbidities in the Midwest @RheumNow #ACR24

Using longitudinal claims data, this study explores the safety of non-conventional combination targeted therapy in adults with psoriatic arthritis (PsA). Key findings: - 42,821 PsA patients analyzed; only 1.1% on combination therapy. - Increased risk of serious infections:… https://t.co/Jghmz9lkLd https://t.co/YqwJlTKcEi

• https://x.com/i/web/status/1858540677661122749
• https://x.com/synovialjoints/status/1858540677661122749/photo/1

Improving the Value of Musculoskeletal Ultrasound in Rheumatology Care #ACR24 MSUS has emerged as a powerful asset in rheumatology, providing a real-time, non-invasive, and cost-effective solution for diagnosing and managing inflammatory arthritis conditions such as RA and PsA.… https://t.co/iH9IZmHhSz https://t.co/am5LoBCdpe

Here’s my take on A#1743 and 1745 on @RheumNow #ACR24 coverage https://t.co/PcRn8Hb4PY https://t.co/2vDyyJUp6W

• RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?
• https://twitter.com/ericdeinmd/status/1858249048085434638

Mental health, sex, and comorbidities are key factors in determining recalcitrant psoriatic arthritis (PsA). Key findings: - 21.7% of patients required ≥4 biologic/targeted synthetic DMARDs. - Female patients and those with depression were more likely to be recalcitrant. - No… https://t.co/I9YYoRnLwh https://t.co/VtnPceVLOZ

• https://x.com/i/web/status/1858533121169498581
• https://x.com/synovialjoints/status/1858533121169498581/photo/1

A Bayesian Network Meta-analysis Phase II/III/IV, placebo-controlled, randomised clinical trials and long-term extension studies of JAKi and TNFi, in adults with RA, PsO, PsA, axial spondyloarthritis axSpA and IBD showed the following: - TNFi was associated with a significantly… https://t.co/FWHgemEAvG https://t.co/3D0nldwmwA

• https://x.com/i/web/status/1858510483290247578
• https://x.com/synovialjoints/status/1858510483290247578/photo/1

📢Late-breaking #2003 🔑 Cappelli et al @jhrheumatology finds hip OA is NOT a significant risk factor for #ICI-IA 🔴#ICI-IA linked to lower mortality #ACR24 #ACRBest @RheumNow

Post hoc analysis of SPIRIT H2H evaluated nail involvement as a measure of ttnt response in PsA. -Pts with nail involvement treated with IXE or ADA had higher SJC and TJC improvement vs those without involvement at W12, W24 and W52. -IXE achieved rapid response for DAPSA-LDA as… https://t.co/SR36qCthQo https://t.co/hI3tD5hATJ

• https://x.com/i/web/status/1858299028125212898
• https://x.com/AdelaCastro222/status/1858299028125212898/photo/1

A study showed the sex differences in serum proteomic profiles of males and females with PsA. Key findings: -Identified 741 unique proteins in male PsA patients vs. controls vs. 31 in females. - Several sex-specific pathways, including immune cell functions and cytokine… https://t.co/erC599Zbuj

• https://x.com/i/web/status/1858250004697391431

A#1746 companion for RA Like plenary for PsA, PBO response incr w time 1%/yr More trials in less affluent countries may be related to increasing PBO response in trials Possible reason: access to health care improves PBO in less affluent areas @RheumNow #ACR24 https://t.co/S3LffF8vPH

• https://twitter.com/ericdeinmd/status/1857803974922903912

📝Bimekizumab 160mg Q4 weeks in r-axSpA and nr-axSpA achieved substantial reductions in MRI inflammation at Wk 16 maintaining to Wk 52. -PBO‑switchers (started at week 16) reached similar levels of improvement as continuous BKZ pts at Wk 52. Abst#1757 #ACR24 @RheumNow https://t.co/m9sdAbFqI9

• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1
• https://x.com/AdelaCastro222/status/1858246229513400637/photo/1

BE MOBILE 1 & 2: Bimekizumab resulted in improvement of SIJ MRI inflammation & structural lesions particularly after 16 wks of treatment and continued on until wk. 52. Supports addtl evidence of BKZ's winning streak in #axSpA @RheumNow #ACR24 abs1757 https://t.co/EUntQIuQC8

• https://x.com/RHEUMarampa/status/1858231890827706410/photo/1

A picture is worth a thousand words—and so are the four abstracts behind it! At #ACR24, I highlight the benefits and risks of apremilast in #PsA. @RheumNow https://t.co/ospR0qEIsd

• Apremilast Benefits and Risks in PsA | RheumNow

Smoking and Rx progression in PsA? -Prospective Canadian cohort of 1736 PsA pts. -Older age, BL SJC, dactylitis, erosions and high ESR were associated with Rx progression. 🚨Cigarette smoking did not appear to be associated with the Rx progression in PsA. Abst#1436 #ACR24… https://t.co/J2IogqOlx8 https://t.co/U6SRmbOE6o

• https://x.com/i/web/status/1858208485722255551
• https://x.com/AdelaCastro222/status/1858208485722255551/photo/1